NCT04019041: A reported trial by Janssen Research & Development, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04019041 |
|---|---|
| Title | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 16, 2019 |
| Completion date | May 19, 2020 |
| Required reporting date | May 19, 2023, midnight |
| Actual reporting date | May 17, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |